Susan Light

2.5k total citations · 1 hit paper
22 papers, 1.9k citations indexed

About

Susan Light is a scholar working on Immunology, Transplantation and Oncology. According to data from OpenAlex, Susan Light has authored 22 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 11 papers in Transplantation and 5 papers in Oncology. Recurrent topics in Susan Light's work include Renal Transplantation Outcomes and Treatments (11 papers), Immune Cell Function and Interaction (5 papers) and Polyomavirus and related diseases (4 papers). Susan Light is often cited by papers focused on Renal Transplantation Outcomes and Treatments (11 papers), Immune Cell Function and Interaction (5 papers) and Polyomavirus and related diseases (4 papers). Susan Light collaborates with scholars based in United States, Germany and Canada. Susan Light's co-authors include Björn Nashan, Mark D. Pescovitz, Robert L. Kirkman, Ginny L. Bumgardner, Robert S. Gaston, F. Vincenti, Lars Bäckman, John F. Neylan, Philip F. Halloran and James F. Burdick and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Blood.

In The Last Decade

Susan Light

22 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation

1998 667 citations F. Vincenti, Robert L. Kirkman et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Susan Light United States	17	878	749	505	410	326	22	1.9k
Jean‐Denis Bignon France	23	607 0.7×	925 1.2×	607 1.2×	338 0.8×	253 0.8×	70	1.9k
Estela Paz‐Artal Spain	25	473 0.5×	1.1k 1.4×	370 0.7×	348 0.8×	192 0.6×	96	2.1k
S. John Swanson United States	26	1.6k 1.9×	998 1.3×	991 2.0×	170 0.4×	266 0.8×	45	3.2k
Adriana I. Colovai United States	29	912 1.0×	1.9k 2.6×	719 1.4×	259 0.6×	324 1.0×	73	3.1k
C. Gautreau France	17	1.2k 1.3×	607 0.8×	822 1.6×	143 0.3×	129 0.4×	35	1.8k
Eric Spierings Netherlands	28	590 0.7×	1.3k 1.7×	428 0.8×	571 1.4×	234 0.7×	99	2.2k
Sebastiaan Heidt Netherlands	30	1.2k 1.4×	1.1k 1.4×	802 1.6×	201 0.5×	216 0.7×	130	2.5k
Helmut E. Feucht Germany	21	1.3k 1.5×	953 1.3×	809 1.6×	120 0.3×	95 0.3×	39	2.1k
Ralph J. Graff United States	20	509 0.6×	767 1.0×	448 0.9×	196 0.5×	143 0.4×	65	2.0k
P. I. Terasaki United States	16	380 0.4×	732 1.0×	320 0.6×	386 0.9×	123 0.4×	32	1.8k

Countries citing papers authored by Susan Light

Since Specialization

Citations

This map shows the geographic impact of Susan Light's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Light with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Light more than expected).

Fields of papers citing papers by Susan Light

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Light. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Light. The network helps show where Susan Light may publish in the future.

Co-authorship network of co-authors of Susan Light

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Light. A scholar is included among the top collaborators of Susan Light based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Light. Susan Light is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Light, Susan, et al.. (2019). FINRA 529 Plan Share Class Initiative encourages firms to self-report violations. Journal of Investment Compliance. 20(3). 20–22. 1 indexed citations

2.

Locke, Frederick L., Joseph Pidala, Barry E. Storer, et al.. (2016). CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 23(3). 405–411. 13 indexed citations

3.

Pescovitz, Mark D., Ginny L. Bumgardner, Robert S. Gaston, et al.. (2003). Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. Clinical Transplantation. 17(6). 511–517. 24 indexed citations

4.

Koch, Martina, et al.. (2002). Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation1. Transplantation. 73(10). 1640–1646. 38 indexed citations

5.

Koch, Martina, et al.. (2002). Long-term Safety, Tolerability and Efficacy of Daclizumab (Zenapax®) in a Two-dose Regimen in Liver Transplant Recipients. American Journal of Transplantation. 2(5). 454–460. 30 indexed citations

6.

Norman, Douglas J., Flavio Vincenti, Angelo M. de Mattos, et al.. (2000). PHASE I TRIAL OF HuM291, A HUMANIZED ANTI-CD3 ANTIBODY, IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM LIVING DONORS1. Transplantation. 70(12). 1707–1712. 42 indexed citations

7.

Krueger, James G., Ian Walters, Megumi Miyazawa, et al.. (2000). Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. Journal of the American Academy of Dermatology. 43(3). 448–458. 100 indexed citations

8.

Przepiorka, Donna, Nancy A. Kernan, Cindy Ippoliti, et al.. (2000). Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 95(1). 83–89. 199 indexed citations

9.

Przepiorka, Donna, Nancy A. Kernan, Cindy Ippoliti, et al.. (2000). Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 95(1). 83–89. 192 indexed citations

10.

Nashan, Björn, Susan Light, Ian R. Hardie, Amy Lin, & J. R. Johnson. (1999). REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION BY DACLIZUMAB1. Transplantation. 67(1). 110–115. 243 indexed citations

11.

Vincenti, F., Robert L. Kirkman, Susan Light, et al.. (1999). Interleukin-2-Receptor Blockade With Daclizumab to Prevent Acute Rejection in Renal Transplantation. The Journal of Urology. 161(3). 1034–1035. 23 indexed citations

12.

Lehky, Tanya, Michael C. Levin, Ryuji Kubota, et al.. (1998). Reduction in HTLV‐I proviral load and spontaneous lymphoproliferation in HTLV‐I–associated myelopathy/tropical spastic paraparesis patients treated with humanized anti‐tac. Annals of Neurology. 44(6). 942–947. 59 indexed citations

13.

Vincenti, Flavio, Björn Nashan, & Susan Light. (1998). Daclizumab: outcome of phase III trials and mechanism of action. Transplantation Proceedings. 30(5). 2155–2158. 62 indexed citations

14.

Vincenti, F., Robert L. Kirkman, Susan Light, et al.. (1998). Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation. New England Journal of Medicine. 338(3). 161–165. 667 indexed citations breakdown →

15.

Ettenger, Robert B., Donald Potter, M.D. Pescovitz, et al.. (1998). HUMANIZED MONOCLONAL ANTI INTERLEUKIN-2 RECEPTOR (IL-2R) ANTIBODY DACLIZUMAB (ZENAPAX®) IN PEDIATRIC (Ped) RENAL TRANSPLANTATION (Tx). Transplantation. 65(Supplement). 92–92. 4 indexed citations

16.

Vincenti, Flavio, Marianne Lantz, Jytte L. Birnbaum, et al.. (1997). A PHASE I TRIAL OF HUMANIZED ANTI-INTERLEUKIN 2 RECEPTOR ANTIBODY IN RENAL TRANSPLANTATION1. Transplantation. 63(1). 33–38. 118 indexed citations

17.

Lantz, Marianne, et al.. (1996). In vivo (phase I) trial and in vitro efficacy of humanized anti-Tac for the prevention of rejection in renal transplant recipients.. PubMed. 28(2). 915–6. 7 indexed citations

18.

Pegelow, Charles H., et al.. (1991). Experience with the use of prophylactic penicillin in children with sickle cell anemia. The Journal of Pediatrics. 118(5). 736–738. 21 indexed citations

19.

Griffin, James D., Susan Light, & David M. Livingston. (1978). Measurements of the molecular size of the simian virus 40 large T antigen. Journal of Virology. 27(1). 218–226. 38 indexed citations

20.

Tenen, Daniel G., et al.. (1977). Purification of simian virus 40 tumor antigen from a line of simian virus 40-transformed human cells.. Proceedings of the National Academy of Sciences. 74(9). 3745–3749. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact